Investigation of Impact of AI on Prostate Cancer Workflow

Launched by CASE COMPREHENSIVE CANCER CENTER · Jul 17, 2025

Keywords

ClinConnect Summary

This clinical trial is studying whether using Artificial Intelligence (AI) can help doctors better find signs of prostate cancer on MRI scans before a biopsy. MRI is a type of imaging test used to look closely at the prostate. The AI software being tested helps analyze these images and gives a score that estimates the chance a spot on the prostate might be cancer. The study compares how well radiologists (doctors who read images) do on their own, how well they do with AI help, and how well the AI works by itself. Participants will have their usual prostate biopsy, and doctors may take a couple of extra samples if the AI spots anything new.

To join the study, people need to be between 55 and 80 years old, have a PSA blood test level between 3 and 10 (PSA is a marker used to help find prostate issues), and be planning to get a prostate biopsy after an MRI. They should not have had prostate cancer before. The MRI images need to be good quality to be included. If chosen, participants can expect their MRI and biopsy results to be used to help improve how AI reads prostate images, which could help doctors in the future detect prostate cancer more accurately.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Plan of care is to undergo a biopsy of the prostate after a pre-biopsy MRI
• • Age 55-80
• • Prostate-specific antigen (PSA) between 3-10 ng/mL
• • No prior diagnosis or treatment of prostate cancer
• Exclusion Criteria:
• • Pre-biopsy MRI is of low quality
• • PI-QUAL score of 1 using PI-QUAL version 2